The diffusion of Performance and Image-Enhancing Drugs (PIEDs) on the Internet: The Abuse of the Cognitive Enhancer Piracetam

Introduction: Performance and image-enhancing drugs (PIEDs), also known as “lifestyle drugs,” are increasingly sold on the Internet to enhance cognitive as well as sexual, muscular, attentive, and other natural capacities. Our analysis focuses on the misuse of the cognitive enhancer piracetam. Methods: A literature review was carried out in PsychInfo and Pubmed database. Considering the absence of peer-reviewed data, review of additional sources of unstructured information from the Internet was carried out between February 2012 and July 2013. Additional searches were conducted using the Global Public Health Intelligence Network (GPHIN), a secure Internet-based early warning system developed by Health Canada and the World Health Organization (WHO), which monitors media reports in six languages, Arabic, Chinese, English, French, Russian, and Spanish. Results: Piracetam is sold via illicit online pharmacies with no need of prescription at low prices. Buyers, mainly healthy individuals, purchase the product to enhance study- and work-related performances as well as for recreational purposes. Its nonmedical use is often associated with the occurrence of side effects such as hallucinations, psychomotor agitation, dysphoria, tiredness, dizziness, memory loss, headache, and severe diarrhoea; moreover, several users declared to have neither felt any cognitive improvement nor psychedelic effects. Conclusions: This is a new and fast-growing trend of abuse that needs to be extensively monitored and studied also by using near real-time and unstructured sources of information such as Internet news and online reports in order to acquire rapid knowledge and understanding. Products sold online might be counterfeits and this enhances related health risks.

[1]  J. McVeigh,et al.  United Kingdom drug situation: annual report to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2012. , 2013 .

[2]  F. S. Bersani,et al.  Drops of madness? Recreational misuse of tropicamide collyrium; early warning alerts from Russia and Italy. , 2013, General hospital psychiatry.

[3]  Suzanne Fergus,et al.  Promoting innovation and excellence to face the rapid diffusion of Novel Psychoactive Substances in the EU: the outcomes of the ReDNet project , 2013, Human psychopharmacology.

[4]  A. Marchi,et al.  Analisi dei report online relativi al potenziale uso errato della benzidamina , 2013 .

[5]  Cinzia Pezzolesi,et al.  Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[6]  O. Corazza,et al.  Consideration of the novel psychoactive substances (‘legal highs’) , 2011 .

[7]  Fabrizio Schifano,et al.  Designer drugs on the internet: a phenomenon out-of-control? the emergence of hallucinogenic drug Bromo-Dragonfly. , 2011, Current clinical pharmacology.

[8]  Michele Piccione,et al.  Is There a Recreational Misuse Potential for Pregabalin? Analysis of Anecdotal Online Reports in Comparison with Related Gabapentin and Clonazepam Data , 2011, Psychotherapy and Psychosomatics.

[9]  R. Oswald,et al.  Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. , 2010, Journal of medicinal chemistry.

[10]  S. Rubinelli,et al.  Cyberdrugs: a cross-sectional study of online pharmacies characteristics. , 2009, European journal of public health.

[11]  Herman D. Tolentino,et al.  Use of Unstructured Event-Based Reports for Global Infectious Disease Surveillance , 2009, Emerging infectious diseases.

[12]  J. Baker,et al.  Counterfeiting in performance- and image-enhancing drugs. , 2009, Drug testing and analysis.

[13]  B. Larance,et al.  Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs. , 2008, Drug and alcohol review.

[14]  B. Winblad Piracetam: a review of pharmacological properties and clinical uses. , 2006, CNS drug reviews.

[15]  Fabrizio Schifano,et al.  Drugs on the web; the Psychonaut 2002 EU project , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[16]  Fabrizio Schifano,et al.  Internet pharmacies and online prescription drug sales: a cross-sectional study , 2005 .

[17]  Fabrizio Schifano,et al.  Importance of Cyberspace for the Assessment of the Drug Abuse Market: Preliminary Results from the Psychonaut 2002 Project , 2003, Cyberpsychology, Behavior, and Social Networking.

[18]  B. Winblad,et al.  Clinical Efficacy of Piracetam in Cognitive Impairment: A Meta-Analysis , 2002, Dementia and Geriatric Cognitive Disorders.

[19]  W. Müller,et al.  Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. , 1997, Biochemical pharmacology.

[20]  D. Oliver,et al.  Cerebral blood flow effects of piracetam, pentifylline, and nicotinic acid in the baboon model compared with the known effect of acetazolamide. , 1996, Arzneimittel-Forschung.

[21]  V. N. Grafova,et al.  [The action of piracetam and its complex with sodium oxybutyrate in the neuropathic pain syndrome]. , 1996, Экспериментальная и клиническая фармакология.

[22]  J. P. Andrade,et al.  Piracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcohol. , 1996, Alcohol.

[23]  R. Brasseur,et al.  Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis. , 1995, Biochemical pharmacology.

[24]  A. Cadete-Leite,et al.  Piracetam impedes hippocampal neuronal loss during withdrawal after chronic alcohol intake. , 1995, Alcohol.

[25]  Cohen Sa,et al.  Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain. , 1993 .

[26]  Jenny Knight,et al.  Promoting innovation , 1988, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[27]  D. Varonos,et al.  Piracetam attenuates the changes in the surface potential of the phosphatidylcholine monolayer produced by alcohols. , 1985, Acta anaesthesiologica Belgica.

[28]  O. Corazza,et al.  [Analysis of online reports on the potential misuse of benzidamine]. , 2013, Rivista di psichiatria.

[29]  Dear Mr,et al.  Inspections, Compliance, Enforcement, and Criminal Investigations , 2012 .

[30]  P. Wiles Statement for publica tion of the APC and ACMD websites Review of the Animal Procedures Committee (APC) and Advisory Council on the Misuse of Drugs (ACMD) , 2010 .

[31]  J. Ballenger efficacy of Piracetam in the Treatment of Tardive Dyskinesia in Schizophrenic Patients : a Randomized, Double-blind, Placebo-controlled Crossover Study , 2009 .

[32]  S. Cohen,et al.  Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain. , 1993, Pharmacology.

[33]  C. Giurgea [Pharmacology of integrative activity of the brain. Attempt at nootropic concept in psychopharmacology]. , 1972, Actualites pharmacologiques.